UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020 Nasdaq:ITRM | MENAFN.COM
Iterum Therapeutics plc announced two data presentations at IDWeek™ 2020, showcasing results from SURE-1 and SURE-2 trials on sulopenem's efficacy in treating uUTI and cUTI. Sulopenem demonstrated superiority over ciprofloxacin in uUTI caused by quinolone non-susceptible pathogens. The company focuses on developing antibiotics against multi-drug resistant pathogens.
Reference News
Iterum Therapeutics plc announced two data presentations at IDWeek™ 2020, showcasing results from SURE-1 and SURE-2 trials on sulopenem's efficacy in treating uUTI and cUTI. Sulopenem demonstrated superiority over ciprofloxacin in uUTI caused by quinolone non-susceptible pathogens. The company focuses on developing antibiotics against multi-drug resistant pathogens.
Iterum Therapeutics plc announced two data presentations at IDWeek™ 2020, showcasing results from SURE-1 and SURE-2 trials on urinary tract infections. Oral sulopenem showed superiority over ciprofloxacin in treating uUTI. The company focuses on developing antibiotics against multi-drug resistant pathogens, with sulopenem in Phase 3 clinical trials.